Home › Smoldering Multiple Myeloma
Smoldering Multiple Myeloma clinical trials recruiting in the U.S.
20 studies for Smoldering Multiple Myeloma are recruiting participants at sites across the United States.
Cities with the most studies
- Boston, MA6 studies
- New York City, NY6 studies
- Atlanta, GA5 studies
- Denver, CO3 studies
- Salt Lake City, UT3 studies
- Durham, NC3 studies
- Columbus, OH3 studies
- Edison, NJ3 studies
- Houston, TX3 studies
By state
- Colorado3 studies
- Florida4 studies
- Georgia5 studies
- Massachusetts6 studies
- Michigan4 studies
- New Jersey3 studies
- New York8 studies
- North Carolina4 studies
- Ohio3 studies
- Texas4 studies
- Utah3 studies
Recently updated studies
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07393282A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06768489Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT03937635Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 16, 2026 · NCT05469893CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
RecruitingObservational studyHealthy volunteers welcome
Ages 30 and older · All sexes · Updated Jul 13, 2026 · NCT06644625A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 8, 2026 · NCT06140524Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 1, 2026 · NCT04776395Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
RecruitingObservational study
Ages 18 and older · All sexes · Updated May 7, 2026 · NCT02269592FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor Disease
Recruiting
Ages 18 and older · All sexes · Updated May 1, 2026 · NCT07446777Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma
RecruitingObservational study
Ages 18 and older · All sexes · Updated Apr 21, 2026 · NCT02726750A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
Recruiting
Ages 18 and older · All sexes · Updated Apr 16, 2026 · NCT05640843Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies
RecruitingObservational study
Ages 18 and older · All sexes · Updated Apr 15, 2026 · NCT05136807Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions
RecruitingObservational study
Ages 18 and older · All sexes · Updated Apr 9, 2026 · NCT05361694Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial
RecruitingObservational study
Ages 18 and older · All sexes · Updated Feb 17, 2026 · NCT06212323Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
Recruiting
Ages 18 and older · All sexes · Updated Dec 1, 2025 · NCT05312255Registry for Adults With Plasma Cell Disorders (PCD's)
RecruitingObservational study
Ages 18 and older · All sexes · Updated Nov 20, 2025 · NCT03717844A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
Recruiting
Ages 18 and older · All sexes · Updated Nov 13, 2025 · NCT06055894The Indiana Myeloma Registry
RecruitingObservational study
Ages 18 and older · All sexes · Updated Nov 10, 2025 · NCT03616483Screening for AL Amyloidosis in Smoldering Multiple Myeloma
RecruitingObservational study
Ages 40 and older · All sexes · Updated Aug 6, 2025 · NCT06365060Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Feb 10, 2025 · NCT05597345From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.